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Abstract: Most scientific efforts towards early detection of ovarian cancer are commonly 
focused on the discovery of tumour-associated antigens (TAA). Autologous antibodies 
against TAA, however, may serve as more sensitive diagnostic markers. They circulate in 
the blood before TAA and are usually more abundant than the TAAs themselves as a result 
of amplification through the humoral immune response. Accumulating evidence also 
suggests that a humoral response already exists during malignant transformation when 
aberrant gene expression is translated into premalignant cellular changes. This article 
reviews the current knowledge about autoantibodies against TAA in ovarian cancer and 
presents current immunoproteomic approaches for their detection. 
Keywords: ovarian cancer; autoantibodies; immunoproteomics 
Abbreviations: 2-DE: two-dimensional electrophoresis; 2D-DITA: two-dimensional 
differential gel electrophoresis analysis of immuno-precipitated tumour antigens;   
DIGE: differential gel electrophoresis; ELISA: enzyme-linked immunosorbent assay;   
EST: expressed sequence tag; FIGO: federation of gynecologists & obstetricians;   
LC: liquid chromatography; MS: mass spectrometry; SEPRA: serological proteome 
analysis; SEREX: Serological analysis of recombinant cDNA expression libraries;   
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TVU: transvaginal ultrasonography; TAA: tumour associated antigen; PPV: positive 
predictive value; PTM: post translational modification. 
 
1. Introduction  
Ovarian cancer is the leading cause of death from gynaecological malignancies [1,2]. It accounts for 
5% of all cancer deaths among women with an estimated 21,880 new cases and 13,850 deaths from 
ovarian cancer in the United States in 2010 [2]. The poor prognosis and high mortality rate associated 
with the disease have not significantly improved over the last 30 years despite advances in treatment [3]. 
This arises as ovarian cancer development is largely asymptomatic resulting in the majority of patients 
(62%) presenting with advanced disease (FIGO stage III and IV) [2]. Current therapies prove effective 
for patients with early stage disease (FIGO stage I/II) where 5-year survival rates range from 73% to 
93%. Their usefulness, however, is limited for patients with advanced stage disease where the 5-year 
survival is only about 30% [2,4]. To date transvaginal ultrasonography (TVU) and serum levels of the 
cancer antigen 125 (CA125) are used alone or in combination to diagnose ovarian cancer. However, 
both approaches have limitations that render them inappropriate for screening the general population. 
TVU has poor diagnostic power where a sensitivity of 84.9%, specificity of 98.2% as well as 
positive predictive value (PPV) of 5.3% for primary ovarian and tubal cancer have been reported in an 
ongoing ovarian cancer screening study [5]. Due to the low lifetime risk of an individual woman 
developing ovarian cancer in the population (1.4%) the minimum requirements for a global screening 
strategy to detect early ovarian cancer are benchmarked at >75% sensitivity and 99.6% specificity [6,7]. 
These values for sensitivity and specificity aim to generate a PPV of 10% where no more than 
10 suspected individuals would need to undergo surgery to confirm one ovarian cancer case. Due to 
potential complications associated with this surgery a PPV less than 10% has been deemed unacceptable.  
CA125, a large glycoprotein from the mucin family, was identified by Bast and colleagues in   
1981 [8]. They subsequently demonstrated that serum CA125 levels over 35 U/mL discriminate 
between healthy and disease cases [9]. Although effective at identifying 80% of patients with late stage 
disease, CA125 is only elevated in less than 50% of early stage I/II ovarian cancer [10,11]. Another 
caveat to the use of CA125 is its elevation in benign conditions including endometriosis, fibroids, 
pelvic inflammatory disease as well as various other malignancies. Consequently the usefulness of 
CA125 as an effective screening marker for identifying early stage disease is limited. Therefore novel 
ovarian cancer biomarkers with high specificity and sensitivity are warranted. 
2. Biomarkers 
To date over thirty biomarkers for ovarian cancer have been reported in the literature   
(reviewed [6,12]). The vast majority are proteins produced by the cancer which can be identified in the 
sera of patients. A major limitation of these proteins as biomarkers is the inability to detect them at 
early stages of cancer development. This arises due to low amounts of the protein being secreted by 
small early stage cancerous lesions and the high dynamic range of proteins in serum (12 orders   
of magnitude) [13]. Int. J. Mol. Sci. 2011, 12                 
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Autologous antibodies against tumour associated antigens (TAAs) may serve as more sensitive 
diagnostic markers. TAAs are tumour specific proteins and peptides that are subject to dysregulation, 
mutation or post translational modification (PTM) during cancer development and have been reported 
as potential causes of an (auto-)antibody response [14]. Antibodies to TAA have three qualities which 
make them ideal candidates for biomarker validation and screening. Firstly, they are detectable at early 
stages of disease. Their production by B-lymphocytes can be activated by a single antigen resulting in 
signal amplification through the humoral immune response. Secondly, autoantibodies are naturally 
resistant to proteolysis and metabolism experienced by other molecules, attributing to their long 
half-life of approximately 21 days [15–17]. This stability allows their reliable detection and facilitates 
their use in the development of diagnostics. Finally, autoantibodies are present in the sera of patients, 
an accessible biological material, and can therefore be analysed through well established techniques [13].  
Various methods like serological analysis of recombinant cDNA expression libraries (SEREX), 
phage display, protein microarray, serological proteome analysis (SEPRA) and immunoaffinity 
chromatography have been used to identify autoantibody biomarkers in various malignancies. 
However, reports on the use of these technologies in ovarian cancer are limited. 
2.1. Serological Analysis of Recombinant cDNA Expression Libraries (SEREX) 
SEREX utilises cDNA libraries for the expression and detection of antigens that elicit a humoral 
immune response in patients. To this end, mRNA extracted from cancer tissue or a tumour cell line is 
converted to cDNA by in vitro methods and subsequently cloned into a bacteriophage for infection of 
Escherichia coli (E. coli) (Figure 1a). During lytic infection the recombinant proteins are expressed 
and can be blotted onto a nitrocellulose membrane for antibody screening with sera (Figure 1b). 
Seroreactive proteins can then be identified by sequencing the phage cDNA from positive plaques. 
SEREX has been useful for identifying several tumour specific antigens that generate a humoral 
immune response in cancers such as those from the kidney, lung, breast and colon [18]. However, this 
approach has inherent limitations that restrict the types of TAAs that may be identified to those that 
can be expressed in a prokaryotic system. This precludes TAAs that require folding mechanisms 
unique to eukaryotes to achieve the correct conformational epitope for recognition and those that are 
subject to PTM, which is a common property of cancer antigens. Furthermore, the TAA encoded in the 
cDNA library may not have the full length protein sequence. Thus those patients that elicit a humoral 
immune response to different antigenic determinants of the same TAA may be missed using this 
system. Furthermore, identification of TAAs is limited to those that are expressed by the patient 
tumour or cell line in which the cDNA library was derived. As the majority of cancers are very 
heterogeneous more than one cDNA library may be required to identify a comprehensive set of 
seroreactive TAAs [19]. Finally, the generation and screening of a cDNA library is labour-intensive, 
not amenable to automation and therefore presents as challenge for high-throughput analysis. 
A study by Stone and colleagues applying SEREX screening to advanced stage ovarian cancer 
patients identified 25 antigens inducing a humoral immune response [19]. The majority of TAAs were 
recognised only by autologous serum, however 6 antigens were found to be immunogenic in at least 2 
of the 25 patient sera screened. A secondary screening using 25 allogenetic sera showed that only 36% 
(9/25) of patients demonstrated immunity against at least one of the 25 TAAs in the panel. Here, only Int. J. Mol. Sci. 2011, 12                 
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7 TAAs (Table 1) were found to generate an autoantibody response in at least 1 of those 9 patients. As 
these autoantibodies were not present in the 45 healthy controls they were thought to have potential as 
diagnostic indicators of ovarian cancer. However, further analyses in a larger cohort of ovarian cancer 
patients are required.  
Lou and co-workers screened a commercially available ovarian carcinoma cDNA library with 
ascites pooled from 5 advanced stage ovarian cancer patients [20]. Twelve novel immunoreactive 
tumour antigens were identified (Table 1). Autoantibodies against one antigen—HSP90—were further 
assessed by ELISA. At a fluorescence ratio cut-off of 2.0 no healthy individuals and only 5% of 
individuals with benign gynaecologic disease demonstrated immunity against HSP90, suggesting that 
HSP90 autoantibodies may reflect a specific response to the cancer. Prevalence of HSP90 
autoantibodies was higher in advanced stage (32%) than early stage ovarian disease (10%). It is 
unclear from this small patient cohort if HSP90 autoantibodies would be suitable for early detection. 
Results from a larger cohort are required. 
Serological screening of a commercially available cDNA library by Lokshin and colleagues 
identified 20 TAAs of which 14 were previously unreported [21]. Amongst these interleukin-8 (IL-8) 
and the corresponding autoantibody were subsequently examined as potential biomarkers. As the 
average serum levels for IL-8 autoantibodies were significantly lower in healthy individuals compared 
to both early stage and late stage ovarian cancer patients it was concluded that they might have 
potential diagnostic value. Receiver operating characteristic (ROC) curves generated from the early 
stage ovarian cancer patient cohort demonstrated IL-8 autoantibodies to have a similar sensitivity 
(65.5%) to that of IL-8 (62.6%) at 98% specificity. Consequently, 79–80% of patients were correctly 
identified by IL-8 or IL-8 autoantibodies. Unfortunately, the mean serum levels for IL-8 autoantibodies 
in patients with benign gynaecological disease were not significantly different from those with ovarian 
cancer. As a result IL-8 autoantibodies alone were not specific enough for screening of early disease. 
However, the utility of IL-8 autoantibodies as a complementary marker to CA125 was promising. A 
combination of the three biomarkers, IL-8, IL-8 autoantibodies and CA125 resulted in an increase in 
the sensitivity to 87.5% compared to CA125 alone (76.8%) without compromising specificity (98%). 
Thus, IL-8 autoantibodies had diagnostic potential when incorporated into a panel of ovarian cancer 
biomarkers, however these need to be investigated in larger cohorts.  
With the aim to identify new therapeutic targets Jin and colleagues performed autologous screening 
of a cDNA library created from a single ovarian cancer patient [22]. Of the 27 seroreactive peptides 
identified 7 were classified as proteins transcribed from expressed sequence tags (EST). EST 1753 
generated protein, referred to as OVA66, was assessed for immunogenicity by ELISA using 48 control 
sera and 113 cancer sera from patients with various malignancies including ovarian cancer (24%). 
Although the difference in OV66 levels were significantly different between cancers and controls, 
OVA66 autoantibodies expression was not restricted to ovarian cancer patients. Autoantibodies were 
detected in 52.6% hepatocellular carcinoma patients, 27.3% colon cancer patients, 23.8% gastric 
cancer patients compared to 22.2% of ovarian cancer patients. Therefore, the TAA OVA66 would not 
be useful as specific ovarian cancer biomarker.  
In conclusion, to date SEREX has enabled the identification of several TAAs that elicit a humoral 
immune response in patients with ovarian cancer [23]. However, further studies are required to 
determine their diagnostic value. Int. J. Mol. Sci. 2011, 12                 
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Figure 1. Schematic outlining autoantibody identification by SEREX. (a) mRNA extracted 
from cancer tissue or cell line is converted to cDNA prior to cloning into a phage vector, 
which is packaged into phage virions and expressed during bacterial infection; (b) Proteins 
generated during lytic infection are blotted onto a membrane and probed with sera. Upon 
detection of cancer specific autoantibody signals phage DNA is sequenced and TAA 
identified through a database search. 
 
Table 1. Identified ovarian cancer autoantibodies and applied technique. 
Technique 
Antigen Source 
(cDNA Library) 
Autoantibody 
Source 
TAA Ref. 
SEREX 
1. Ovarian cancer cell line 
2. Pool of ovarian tumour 
lysates 
3. Normal human testes 
Serum 
p53 
NY-ESO-1 
Topoisomerase IIα 
Ubiquilin-1 
Homeobox B6 
HMBA inducible protein 
HDCMA 18P protein 
[19] 
Commercial cDNA library  Ascites  HSP90  [20] 
Commercial cDNA library  Serum  IL-8  [21] 
Ovarian cancer tumour 
lysate 
Serum OVA66  [22] 
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Table 1. Cont. 
Technique 
Antigen Source 
(cDNA Library) 
Autoantibody 
Source 
TAA Ref. 
Phage 
Display 
Random peptide library  Ascites  Mimic peptide CVPELGHEC  [24] 
Ovarian cancer cell line  Serum 
RCAS1 
Signal recognition protein-19 
AHNAK-related sequence 
NASP 
Nijmegen breakage syndrome 1 
Ribosomal protein L4 
Homo Sapiens KIAA0419 gene 
product 
Eukaryotic initiation factor 5A 
Casein kinase II 
Chromodomain helicase DNA-
binding protein 1 
[25] 
Protein 
Microarray 
ProtoArray (V3.0)  Serum  94 Autoantigens  [26] 
ProtoArray (V4.0)  Ascites 
L-aminoadipate-semialdehyde 
dehydrogenase-phosphopantetheinyl 
transferase (AASDHPPT) 
[27] 
Ovarian cancer cell line 
(exosome derived) dot blot 
array 
Serum 
Nucleophosmin 
Cathepsin D 
SSX common antigen 
GRP78 
P53 
Placental-type alkaline phosphatase 
Heat shock protein 90 
NY-ESO-1 
Survivin 
TAG72 
CA125 
HoxA7 
[28] 
Immuno-
affinity 
Purification 
Methods 
Ovarian adenocarcinoma 
cell line lysate 
Serum 
A-kinase anchor protein 9 
Eukaryotic translation initiation 
factor 4γ 
Midasian 
RAD50 
Talin1 
Vinculin 
Vimention 
Centrosome-associated protein 350 
[29] 
Malignant ovarian tissue 
lysate 
Plasma S100A7  [30] 
Ovarian tissue lysate  Serum  Stress-induced phosphoprotein-1  [31] 
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2.2. Phage Display 
In a phage display proteins are expressed as fusions of the viron capsid proteins, thus eliminating 
the need for infection of bacteria for protein production like in SEREX (Figure 2a). Phage clones with 
seroreactive surface proteins are selected by incubating the pool with autoantibodies bound to protein 
G-sepharose. Routinely, phage clones that are recognised by autoantibodies in the sera of healthy 
individuals are depleted from the pool before repetitive biopanning with autoantibodies in the sera of 
cancer patients (Figure 2b). This ensures that phage clones identified have a cancer specific immune 
response. Although this approach enables extensive identification of cancer autoantibodies it has the 
same limitations encountered by SEREX: Proteins expressed are restricted to those that are found in 
the source of the cDNA library, can be expressed by phage and lack PTMs or conformational epitopes.  
Vidal and co-workers utilised a phage display library containing 10
8–10
9 peptide sequences   
to screen for autoantibodies in the ascites of a patient with stage IV papillary serous ovarian   
carcinoma [24]. Peptide sequence CVPELGHEC was found to be displayed by 86% of the phage 
clones isolated in the screening and was subsequently assessed for immunogenicity by ELISA. Patients 
with metastatic gastrointestinal cancer, non-malignant liver cirrhosis, benign gynaecological disease 
and healthy individuals all demonstrated low autoantibody reactivity of less than 14%. Although 
58.8% of stage IV ovarian cancer patients analysed had anti-CVPELGHEC autoantibodies, only 7.1% 
of patients with stage III ovarian cancer demonstrated reactivity. These findings suggest that 
autoantibodies to CVPELGHEC would not be a useful biomarker due to a high false negative rate. 
Chatterjee and colleagues utilised phage display in conjunction with protein microarray to identify 
novel antigens and validate autoantibodies present in the sera of patients as biomarkers for ovarian 
cancer [25]. Upon biopanning of a phage display cDNA library 480 positive plaques were identified. 
These plaques were subsequently screened with sera from patients with ovarian cancer, borderline 
tumours, benign gynaecological disease, endometrial cancer and healthy controls. Only 45 of the 
antigens were identified as generating a specific immune response in ovarian cancer patients. A panel 
of the 6 best clones, as determine by ROC curve analysis, demonstrated an average sensitivity and 
specificity of 32% and 94%, respectively. Upon sequencing of the phage cDNA clones these 6 
antigens were not natural gene products but formed a novel sequence when recombinantly expressed 
as a phage fusion protein. Termed mimotopes, it was proposed that these fusion proteins demonstrate 
seroreactivity in patients due to molecular mimicry of the epitopes of native proteins that have elicited 
the immune response. These mimotopes account for approximately 80% of the antigens identified by 
this approach and may have clinical utility as antigens for autoantibody screening for ovarian cancer. 
The remaining 10 antigens (Table 1) that represent native gene products have been reported in other 
malignancies and therefore an autoantibody response to these proteins as ovarian cancer specific 
biomarkers requires further validation. 
Phage display has enabled the identification of various antigens that elicit autoantibody responses in 
ovarian cancer. However the majority of those are mimotopes of native proteins. Thus the identity of 
those antigens may need to be determined before the corresponding autoantibodies are investigated  
as biomarkers.  
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Figure 2. Schematic outlining autoantibody identification by phage display. (a) mRNA 
extracted from cancer tissue or cell line is converted to cDNA. Phage vectors encoding 
human cDNA sequences are assembled into virions for expression as recombinant capsid 
fusion proteins; (b) Phage clones presenting immunoreactive peptides are 
immunoprecipitated from the pool with antibodies from the sera of healthy individuals. 
Unbound clones are immunoprecipitated with antibodies from the sera of cancer patients, 
eluted and amplified through infection of E. coli. Phage clones isolated by multiple rounds 
of immunoprecipitation with antibodies from cancerous sera are then sequenced and 
antigenic proteins identified.  
 
2.3. Protein Microarray 
Protein microarrays enable the identification of protein-protein interactions, such as antibody-antigen 
binding, in a high-throughput and automated setting (Reviewed [32,33]). The two types used to 
explore the immunoproteome are termed forward-phase and reverse-phase microarray depending on 
the nature of the capture/bait molecule. Reverse-phase microarrays employ the antigenic nature of 
proteins (the bait) to capture antibodies (the prey). The source of the bait may be from a commercial 
recombinant protein library arrayed onto a slide (Human ProtoArray, Invitrogen, Carlsbad, CA) [34], 
cell free cDNA expression and protein immobilisation onto a slide [35] or lysates from cancer tissue or 
cell lines [36–38]. In the case of cell lysates, proteins require liquid phase fractionation, incorporating 
isoelectric focusing and reverse-phase liquid chromatography (LC), prior to printing onto an array 
support. The array can then be probed with patient or control sera in a multiplexed approach followed 
by incubation with fluorophore conjugated anti-human IgG secondary antibody (Figure 3). 
Immunoreactive fractions can be subsequently detected and data analysed. This technology can be 
used to identify novel TAAs or validate known TAAs by screening the sera from several patients.  Int. J. Mol. Sci. 2011, 12                 
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Forward-phase microarrays utilise immobilised antibodies (bait) to capture TAAs (prey). 
Immobilisation of antibodies to a range of support medias can involve covalent linking (aldehyde), 
adsorption (poly-L-lysine), affinity interaction (biotin-streptavidin, Protein G) and capture (agarose, 
polyacrylamide) that vary in binding capacity and effect on antibody conformation/activity [39]. Using 
in house or commercially available monoclonal antibody microarrays (BD Clontech AB Microarray 
500, Mountain View, CA) TAAs from tumour cell lysates are captured and detected by sandwich 
ELISA. Using this approach Qin and coworkers demonstrated that novel TAAs specific for prostate 
cancer could be identified using purified and labelled autoantibodies from serum [40]. However, the 
use of two antibodies that recognise different epitopes of a single antigen is required. Alternatively, 
cancer and control tissue lysates can be fluoresently labelled for direct detection of an interaction. In 
both protein microarray approaches immunoreactive antigens can be subsequently identified by MS. 
To date only reverse-phase protein microarrays have been employed to identify novel TAAs or 
characterise known TAAs and their respective autoantibodies in ovarian cancer.  
Gnjatic and colleagues used a commercially available protein microarray (V4.0, Invitrogen, 
Carlsbad, CA) with 8277 human proteins to identify autoantibodies in ovarian cancer sera [34]. Of the 
arrayed proteins, 197 demonstrated a greater seroreactivity and stronger fluorescent signal in the 
patient cohort compared to the healthy controls. The authors note that further studies are ongoing to 
elucidate the diagnostic potential of these autoantibodies.  
An earlier study by Hudson et al. similarly used the ProtoAray human protein microarray (V3.0, 
Invitrogen) to identify seroreactive antigens in ovarian cancer [26]. At that time only 60% of the 
recombinant proteins of the currently available array were present. Ninetyfour TAAs were identified as 
having immunogenicity specific to ovarian cancer patients when compared to healthy individuals, 
some of which were not identified in the study by Gnjatic and others [34]. However, no further 
exploration of the autoantibodies to these TAAs has been carried out to date.  
The same commercial protein microarray (V4.0, Invitrogen, Carlsbad, CA) was used to screen a 
pool of ascites samples from 30 patients with serous ovarian carcinoma by another group [27]. Here, 
only 10 proteins were identified as having seroreactivity specific for ovarian cancer. Of the identified 
proteins L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (AASDHPPT) 
was found to have the greatest signal intensity compared to controls. However, upon further analysis of 
ascites from 100 patients by ELISA, anti-AASDHPPT autoantibodies at a very high titre were only 
present in a single patient that was used in the preliminary screening. For this reason pooling of 
samples is controversial [41,42]. 
Conversely, Taylor and co-workers used a dot-blot protein array to define the immunogenicity of 
12  previously identified autoantigens in ovarian cancer patients (Table 1) [28]. Of the 12 TAAs 
analysed the mean autoantibody level against nucleophosmin, cathepsin D and SSX common antigen 
was significantly greater in patients at each stage (I–IV) compared to healthy or benign controls. All 
other autoantibodies assayed were able to discriminate between cancer patients and healthy controls to 
some extent. Further analysis was therefore performed to determine the specificity of the immune 
response against these antigens in ovarian cancer compared to other malignancies. Of the 
6 autoantigens analysed placental-type alkaline phosphatase (PLAP) autoantibodies demonstrated the 
greatest specificity for ovarian cancer, however immunoreactivity in stage I patients was not 
significantly different to healthy or benign controls. It was therefore concluded from this study that a Int. J. Mol. Sci. 2011, 12                 
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two-tiered approach should be taken. Firstly a panel of autoantigens such as nucleophosmin, 
cathepsin D and SSX common antigen, characterised in this study, would be employed to discriminate 
between cancer patients and those with benign gynaecological disease. Secondly, subsequent testing 
for ovarian cancer by means of specific marker(s) such as PLAP would follow.  
Overall protein microarray is a promising technique that enables the identification and 
characterisation of various autoantibodies specific to ovarian cancer. However, most of the 
autoantibodies identified have not been validated regarding their diagnostic value.  
Figure 3. Schematic outlining autoantibody identification by reverse-phase protein 
microarray. Microarray slides spotted with recombinant proteins are incubated with sera 
from cancer patients or healthy controls. Autoantibodies captured by proteins present in the 
array are visualised through incubation with fluorophore conjugated anti-human IgG 
secondary antibody. Differential signals between cancer and control protein microarrays 
are subjected to statistical analysis to identify autoantibodies specific for cancer. 
 
2.4. Serological Proteome Analysis (SEPRA) 
Serological proteome analysis utilises the separation of proteins by two-dimensional gel 
electrophoresis (2-DE) combined with Western blotting to screen patient sera for autoantibodies 
against cancer specific antigens (Figure 4). 2-DE is a classical proteomic technique that enables the 
separation of proteins in a complex mixture based on charge and molecular weight (Mr). Separation in 
the first dimension exploits the acidic or basic properties of proteins, which is based on the content of 
positively or negatively charged amino acid side chains. Under an applied electric field proteins will 
migrate in a pH gradient until they reach their isoelectric point (pI) where the sum charge equals 
zero [43]. In the second dimension, proteins become separated based upon their molecular weight 
using conventional SDS-polyacrylamide gel electrophoresis (SDS-PAGE), where low molecular 
weight proteins migrate to the anode more rapidly than heavier proteins. 
Proteins and peptides isolated from cancer cell lines or tumour tissue are separated by 2-DE, 
electrophoretically transferred onto a membrane and subsequently probed with patient or control sera 
for biomarker discovery and validation. Autoantibodies bound to antigens can then be detected by 
probing the membrane with a secondary antibody that is raised against the fragment crystallisable (Fc) 
region of human IgG. The secondary antibody is typically linked to an enzyme, such as horse radish 
peroxidase (HRP), which catalyses a chemoluminescent reaction in the presence of substrate that can 
Protein microarray Probed with cancer or control sera Detection of autoantibodies Protein microarray Probed with cancer or control sera Detection of autoantibodiesInt. J. Mol. Sci. 2011, 12                 
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be visualised on X-ray film. Alternatively, the secondary antibody may be conjugated to a detectable 
fluorescent tag (Cy5, Cy3, etc.) that can be visualised by scanning of the membrane with a 
fluorescence scanner. Seroreactive proteins specific to cancer can then be identified by mass 
spectrometry (MS).  
SEPRA, in contrast to SEREX and phage display, enables the detection of proteins that have 
undergone PTMs and allows the assessment of several 1000 proteins simultaneously on a single format 
under defined conditions [44]. Limitations of detecting autoantibodies by SEPRA stem from the 
inherent limitations of 2-DE. Those are the potential loss of small (<15 kDa), very large (>200 kDa), 
very acidic (pI < 3), very basic (pI > 10) and very hydrophobic proteins as well as the inability to 
detect TAA with conformational epitopes due to the denaturing conditions.  
Figure 4. Schematic outlining autoantibody identification by SEPRA. Cancer tissue lysates 
are subjected to two-dimensional electrophoresis prior to electrophoretic transfer onto a 
low fluorescent PVDF membrane. Serum from cancer patients or healthy controls is used 
to probe the membrane and captured autoantibodies detected by incubation with 
fluorophore conjugated anti-human IgG secondary antibody. Blots are imported into 
computational software where they can be viewed in multichannel mode and merged to 
enable identification of immunoreactive spots specific to cancer. Protein spots of interest 
are excised from a replicate gel and analysed by mass spectrometry for identification. 
 
Several reports have been published using SEPRA for successful identification of autoantibodies 
against TAAs in cancers of the kidney [45], lung [46], stomach [47], breast [48,49], pancreas [50] and 
other organs [51]. The first study using SEPRA to investigate the presence of ovarian cancer specific 
autoantibodies and their potential as ovarian cancer biomarkers was published by Barua et al [52]. 
Overall, the level of autoantibodies detected in sera was significantly higher for ovarian cancer patients 
compared to controls. While a similar proportion of sera samples from cancer patients reacted   
against healthy tissue protein lysates (81%) as well as tumour lysates (69%), spot differences in   
two-dimensional Western blots demonstrated the presence of unique cancer antigens. Although this 
principle had been previously established for several other cancers [53], this study demonstrated that 
there are ovarian cancer specific autoantibodies that may have biomarker potential. However, the Int. J. Mol. Sci. 2011, 12                 
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antigens were not identified in this study and to date there are no further reports on the identification of 
biomarkers for ovarian cancer by SEPRA. 
2.5. Immunoaffinity Purification Methods 
Affinity purification has been widely used to enrich targeted proteins of interest from a complex 
sample. Recently, purified autoantibodies from the sera of cancer patients or healthy controls have 
been used to generate immunoaffinity columns that capture autoantigens from cancer tissue 
lysates  [54–56]. Termed multiple affinity protein profiling (MAPPing), this approach first utilises 
autoantibodies from healthy individuals to capture autoantigens that are present in cancer tissue lysates 
(Figure 5a). This first dimensional separation effectively removes autoantigens that do not elicit a 
cancer specific immune response but are present in the healthy population. Unbound proteins are then 
applied to an immunaffinity column created with autoantibodies from cancer patients (second 
dimension) (Figure 5b). Captured TAAs are subsequently eluted and identified by online tandem MS. 
This two-dimensional chromatography based separation ensures that the identified antigens reflect a 
cancer specific immune response and identify autoantibodies present in patient sera which are potential 
biomarkers. Caron and colleagues [54] developed this technique to identify autoantibodies as 
biomarkers for breast and colon cancer. However, since published in 2007, no other group has 
described the use of this approach for cancer biomarker discovery.  
Figure 5. Purification of TAAs from cancer tissue lysates using two dimensional affinity 
chromatography. (a) Autoantigens that are not specific to cancer (blue circles) are captured 
in the first dimension by autoantibodies from healthy subjects; (b) Proteins that are not 
captured in the first dimension (flow through; square and diamond) are subjected to the 
second dimension where cancer specific TAAs will be captured (square) by autoantibodies 
from cancer patients. The subsequent elution fractions from both columns are assessed by 
LC-MS/MS. LC: liquid chromatography; MS: mass spectrometry. 
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Immunoprecipitation of cancer lysates using autoantibodies acquired from serum of cancer patients 
and healthy individuals has also been explored. Philip [29] incubated lysates from two ovarian 
adenocarcinoma cell lines with pooled antibodies from cancer or control sera that are coupled to 
protein A/G beads (Figure 6). Following immunocapture and elution of antigens, samples were 
fractionated and analysed by LC-MS/MS. Several autoantigens and their respective autoantibodies, 
specific to ovarian cancer, were identified. Of those, eight autoantigens were found to be precipitated 
from all 5 different pools of cancer sera (Table 1). Although promising, no further analysis was 
performed to determine the prevalence or diagnostic value of these autoantibodies. 
Figure 6. Immunoprecipitation method employed by Philip et al. [29] to identify ovarian 
cancer specific TAAs. Pooled healthy or cancer sera from patients were incubated with 
protein A/G sepharose beads before incubation with lysates from an ovarian cancer cell 
line. Co-eluted autoantibodies were separated from the autoantigens by liquid 
chromatography (LC) and were subsequently identified using mass spectrometry (MS). 
S/N: supernatant. 
 
 
In a different approach, Gagnon and colleagues [30] used pre and post operative sera from ovarian 
cancer patients to identify autoantibodies whose concentration decline after treatment, reflecting 
decreased tumour load, and therefore potentially having diagnostic value. Firstly, antigens present in 
the cancer tissue lysates were immunoprecipitated with plasma antibodies from the same patient that 
were chemically cross-linked to protein-G sepharose beads (Figure 7a). Eluted fractions were then 
fluorescently labelled and subjected to differential gel electrophoresis (DIGE) analysis (Figure 7b). 
Autoantigens that were present at a higher intensity in pre operative samples than post operative 
samples on the DIGE gel were indicative of a change in autoantibody response due to treatment.  
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tumour antigens (2D-DITA) Gagnon et al. identified autoantigen S100A7 to have the greatest   
differential signal [30].  
Figure 7. Immunoprecipitation method employed by Gagnon et al [30] to identify 
autoantigens and their respective autoantibodies in ovarian cancer patients. (a) Pre or post 
operative serum antibodies are cross-linked to protein G sepharose beads prior to 
incubation with tissue lysate from the same patient; (b) Autoantibodies that are indicative 
of cancer decline upon treatment (purple antibody) and capture proportionally less 
autoantigen (purple squares). Eluted fractions are fluorescently labelled and subjected to  
2-DE (DIGE). Protein spots that are only immunoprecipitated by the pre operative antibody 
pool (red spots) or those with a greater intensity are excised from the gel and identified by 
mass spectrometry. DIGE: Differential gel electrophoresis; Ab: Antibody; green spots: 
autoantigens immunoprecipitated by the post operative antibody pool only; yellow spots: 
autoantigens immunoprecipitated by both the pre and post operative antibody pool. 
 
The prevalence of S100A7 autoantibodies in ovarian cancer patients, patients with benign 
gynaecological disease and healthy controls was analysed by ELISA. The mean plasma levels of 
S100A7 autoantibodies were significantly greater in both early stage and advanced stage ovarian 
cancer patients when compared to healthy controls. However, when analysing the mean plasma 
S100A7 autoantibody levels of cancer patients versus those with benign ovarian disease, only patients 
with advanced cancer had higher mean S100A7 autoantibody levels. Furthermore, analysis of S100A7 
autoantibodies alone or as a composite biomarker to CA125 showed that the sensitivity and specificity 
remained inferior to CA125 alone at detecting ovarian cancer. However, the authors concluded that 
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further analyses in a larger patient cohort were required to determine the real diagnostic potential of 
S100A7 autoantibodies. 
Similarly, Kim and co-workers employed 2D-DITA to analyse the sera from fourteen serous 
ovarian cancer patients before and after treatment for autoantibodies [31]. From the 36 differential 
proteins identified in the DIGE gels, stress-induced phosphoprotein-1 (STIP-1) had a 1.16-fold higher 
expression in pre treatment sera compared to post treatment sera. Noted as having one of the highest 
differential signals, the stimulation of a humoral immune response by STIP-1 was assessed in 
68 ovarian cancer patients (stages unknown), patients with borderline ovarian tumours (n = 13) and 
healthy controls (n = 63) by ELISA. The mean STIP-1 concentration in the sera of ovarian cancer 
patients was significantly different to healthy controls. These results suggest a potential value of   
STIP-1 autoantibodies as a biomarker for ovarian cancer; however, the relevance for detecting early 
stage disease remains unclear. 
3. Conclusion 
Novel biomarkers are urgently required to detect early ovarian cancer and reduce the current 
mortality rate. Evidence suggests that a single biomarker is not sufficiently sensitive or specific for 
implementation of a global screening strategy, thus a panel of cancer specific biomarkers will need to 
be generated. Autoantibodies have potential as early diagnostic markers for disease, which has been 
demonstrated for ovarian and other cancers. The presence of autoantibodies during early stages of 
malignancy and their inherent stability in sera would enable the detection of cancer at a stage when 
treatments are most effective. Our recent studies have employed immunoprecipitation and 2D-DITA to 
identify autoantibodies specific for ovarian cancer. We are now investigating autoantibodies that 
recognise linear or conformational epitopes of ovarian TAAs. The coupling of immunoaffinity 
chromatography with existing DIGE technology and SERPA aims to broaden the scope of 
autoantigens that can be detected. Thus, this approach has the potential to yield novel autoantibodies 
that can be used for early detection of ovarian cancer. Furthermore, validation of autoantibody 
biomarkers is a vital step towards clinical implementation. However there is currently a disconnect 
between the discovery stage and validation which comes through in a number of studies cited in 
this review. 
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